Philips Recognized with ‘A’ Score for its Climate Action Leadership

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company has been recognized for its climate action leadership by global environmental non-profit CDP. Thanks to its actions to cut emissions, mitigate climate risks, and develop the low-carbon economy, Philips has secured a place on CDP’s ‘A List’ for the ninth consecutive year.

“With health systems and consumers increasingly committed to making more sustainable choices and to climate action, we remain convinced that doing business sustainably is the only way forward,” said Frans van Houten, CEO of Royal Philips. “Our ongoing actions to embed sustainability in our solutions, our operations, and across the supply chain, have once again been recognized with a place on CDP’s prestigious benchmark. I am proud that the creativity and inspiration of our global workforce continue to make a difference in creating a healthier and more sustainable world.”

CDP’s annual environmental disclosure and scoring process is widely recognized as the gold standard of corporate environmental transparency. Its scoring methodology assesses companies on the comprehensiveness of their disclosure, awareness and management of environmental risks and demonstration of best practices associated with environmental leadership, such as setting ambitious and meaningful targets.

Global recognition

To achieve its vision of making the world healthier and more sustainable through innovation, Philips employs a comprehensive set of commitments across all the Environmental, Social, and Governance (ESG) dimensions that guide the execution of company strategy. Philips is already carbon neutral in its operations and is set to further reduce its CO2 emissions in line with 1.5°C global warmings, for example by further improving the energy efficiency of its products during the customer use phase and teaming up with customers and stakeholders to decarbonize healthcare. The company has also set ambitious circular economy objectives, such as generating 25% of its revenue from circular products, services and solutions by 2025. Philips is also taking action to drive the significant reduction of greenhouse gas emissions in its supply chain.

The company’s longstanding commitment to doing business responsibly and sustainably has received widespread recognition. For example, Philips has achieved top positions in the global Dow Jones Sustainability Indices and Sustainalytics rankings, and the company was awarded a top ESG score of 90 out of 100 by S&P Global Ratings. Moreover, Philips was the first health technology company to have its carbon emission targets for the 2020 – 2040 period assessed and approved by the Science-Based Targets initiative (STBi). 

More information about how Philips is partnering with stakeholders to drive environmental, social, and governance priorities and make a global impact, is available here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy